|
|
|
|
LEADER |
00000pam a22000004a 4500 |
001 |
4741400 |
003 |
ICU |
005 |
20031021181500.0 |
008 |
010308s2002 nyua b 001 0 eng |
010 |
|
|
|a 2001024251
|
020 |
|
|
|a 0471986550 (cased)
|
035 |
|
|
|a 2001024251
|
040 |
|
|
|a DLC
|c DLC
|d DLC
|d OCoLC
|d OrLoB-B
|
042 |
|
|
|a pcc
|
050 |
0 |
0 |
|a RM301.25
|b .P75 2002
|
082 |
0 |
0 |
|a 615/.19
|2 21
|
245 |
0 |
0 |
|a Principles and practice of pharmaceutical medicine /
|c Andrew J. Fletcher ... [et al., editors].
|
260 |
|
|
|a New York :
|b Wiley,
|c c2002.
|
300 |
|
|
|a xii, 541 p. :
|b ill. ;
|c 25 cm.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
0 |
|g Sect. I.
|t Overview of Pharmaceutical Medicine --
|g 1.
|t Pharmaceutical Medicine as a Medical Speciality /
|r Michael D. Young --
|g 2.
|t What Pharmaceutical Medicine Is and Who Does It /
|r W. Wardell, Susan Toland and Anthony W. Fox --
|g 3.
|t Competency-based Training System for Clinical Research Staff /
|r Jay D. Miller --
|g Sect. II.
|t Drug Discovery and Development --
|t Introduction /
|r Lionel D. Edwards and Anthony W. Fox --
|g 4.
|t Drug Discovery: Design and Serendipity /
|r Leslie J. Molony --
|g 5.
|t Pharmaceutics /
|r Anthony W. Fox --
|g 6.
|t Non-clinical Toxicology /
|r Frederick Reno --
|g 7.
|t Informed Consent /
|r Anthony W. Fox --
|g 8.
|t Good Clinical Practices /
|r Wendy Bohaychuk and Graham Ball --
|g 9.
|t Quality Assurance, Quality Control and Audit /
|r Donna Cullen --
|g 10.
|t Phase I: The First Opportunity for Extrapolation from Animal Data to Human Experience /
|r Stephen Curry, Dennis McCarthy and Heleen H. DeCory /
|r [et al.] --
|g 11.
|t Phase II and Phase III Clinical Studies /
|r Anthony W. Fox --
|g 12.
|t Phase IV Drug Development: Post-marketing Studies /
|r Lisa R. Johnson-Pratt --
|g 13.
|t Over-the-counter Medicines /
|r Paul Starkey --
|g Sect. III.
|t Special Populations --
|t Introduction /
|r Lionel D. Edwards --
|g 14.
|t Drug Research in Older Patients /
|r Lionel D. Edwards --
|g 15.
|t Drug Development Research in Women /
|r Lionel D. Edwards --
|g 16.
|t Clinical Research in Children /
|r Lionel D. Edwards --
|g Sect. IV.
|t Applied Aspects of Drug Development --
|t Introduction /
|r Anthony W. Fox --
|g 17.
|t Biotechnology Products and Their Development /
|r David Shapiro and Anthony W. Fox --
|g 18.
|t Orphan Drugs /
|r Bert Spilker --
|g 19.
|t Pharmacoeconomics: Economic and Humanistic Outcomes /
|r Raymond J. Townsend, Jane T. Osterhaus and J. Gregory Boyer --
|g 20.
|t Pharmacoepidemiology and the Pharmaceutical Physician /
|r Hugh Tilson --
|g 21.
|t Statistical Principles and Their Application in Biopharmaceutical Research /
|r Dan Anbar --
|g 22.
|t Data Management /
|r T. Y. Lee and Michael Minor --
|g 23.
|t Patient Compliance /
|r Jean-Michel Metry --
|g 24.
|t Complementary Medicines /
|r Anthony W. Fox --
|g Sect. V.
|t Drug Registration --
|t Introduction /
|r Anthony W. Fox --
|g 25.
|t United States Regulations /
|r William Kennedy --
|g 26.
|t Emergency and Compassionate-use INDs and Accelerated NDA or ANDA Approvals - Procedures, Benefits and Pitfalls /
|r Anthony W. Fox --
|g 27.
|t Japanese Regulations /
|r Etienne Labbe --
|g 28.
|t The Development of Human Medicines Control in Europe from Classical Times to the Year 2000 /
|r John Griffin --
|g 29.
|t Ethnic Issues in Drug Registration /
|r Lionel D. Edwards, J. M. Husson and A. Kumagai /
|r [et al.] --
|g Sect. VI.
|t Medical Services --
|t Introduction /
|r Anthony W. Fox --
|g 30.
|t An Introduction to Medical Affairs /
|r Gill Price --
|g 31.
|t Drug Labeling /
|r Anthony W. Fox --
|g 32.
|t Organizing and Planning Local, Regional, National and International Meetings and Conferences /
|r Zofia E. Dziewanowska, Linda Packard and Lionel D. Edwards --
|g 33.
|t Drug Surveillance /
|r Howard J. Dreskin and Win M. Castle --
|g 34.
|t Disease Management - What Does It Mean? /
|r Roy Lilley --
|g 35.
|t Publishing Clinical Studies /
|r Anthony W. Fox --
|g Sect. VII.
|t Legal and Ethical Aspects --
|t Introduction /
|r Sara Croft and Tim Pratt --
|g 36.
|t Pharmaceutical Product Liability /
|r Han W. Choi and Howard B. Yeon --
|g 37.
|t Patents /
|r Gabriel Lopez --
|g 38.
|t Fraud and Misconduct in Clinical Research /
|r Frank Wells --
|g Sect. VIII.
|t Business Aspects --
|g 39.
|t The Multinational Corporations: Cultural Challenges, the Legal/Regulatory Framework and the Medico-commercial Environment /
|r R. Drucker and R. Graham Hughes --
|g 40.
|t Outsourcing Clinical Drug Development Activities to Contract Research Organizations (CROs): Critical Success Factors /
|r John R. Vogel --
|g 41.
|t The Third World /
|r Gamal Hammad --
|g 42.
|t Financial Aspects of Clinical Trials /
|r R. Graham Hughes and N. Turner --
|g 43.
|t The Impact of Managed Care on the US Pharmaceutical Industry /
|r Robert Chaponis, Christine Hanson-Divers and Marilyn J. Wells.
|
650 |
|
0 |
|a Drug development.
|0 http://id.loc.gov/authorities/subjects/sh97007921
|
650 |
|
0 |
|a Drugs
|x Research.
|0 http://id.loc.gov/authorities/subjects/sh85039745
|
650 |
|
0 |
|a Pharmacology.
|0 http://id.loc.gov/authorities/subjects/sh85100599
|
650 |
|
7 |
|a Drug development.
|2 fast
|0 http://id.worldcat.org/fast/fst00898670
|
650 |
|
7 |
|a Drugs
|x Research.
|2 fast
|0 http://id.worldcat.org/fast/fst00898894
|
650 |
|
7 |
|a Pharmacology.
|2 fast
|0 http://id.worldcat.org/fast/fst01060259
|
700 |
1 |
|
|a Fletcher, Andrew J.
|0 http://id.loc.gov/authorities/names/n87843441
|1 http://viaf.org/viaf/69009100
|
901 |
|
|
|a ToCBNA
|
903 |
|
|
|a HeVa
|
035 |
|
|
|a (OCoLC)46462793
|
929 |
|
|
|a cat
|
999 |
f |
f |
|i ba7584fe-2f6d-5c16-9300-62c4d31fe63d
|s 4b4509b7-4759-5af5-ada6-599e7bf65eaa
|
928 |
|
|
|t Library of Congress classification
|a RM301.25 .P75 2002
|l JCL
|c JCL-Sci
|i 4328871
|
927 |
|
|
|t Library of Congress classification
|a RM301.25 .P75 2002
|l JCL
|c JCL-Sci
|e MARO
|e CRERAR
|b 61101784
|i 7345733
|